Influenza A Vaccine - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510252417

Publication Date:

October 8, 2024

Pages:

123

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Influenza A Vaccine was estimated to be worth US$ 7292 million in 2023 and is forecast to a readjusted size of US$ 11090 million by 2030 with a CAGR of 6.3% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Influenza A Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Influenza A Vaccine by region & country, by Type, and by Application.
The Influenza A Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Influenza A Vaccine.
麻豆原创 Segmentation
By Company
Novartis
Sanofi
GSK
Medimmune
Abbott
Mitsubishi Tanabe Pharma
Merck
Sinovac Biotech
Hualan Biological Engineering
Changsheng Bio-Technology
Beijing Tiantan Bio-Products
Segment by Type:
Intramuscular Vaccine
Nasal Spray Vaccine
Segment by Application
3-18 Years Old
Above 18 Years Old
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Influenza A Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Influenza A Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Influenza A Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Influenza A Vaccine Product Introduction
1.2 Global Influenza A Vaccine 麻豆原创 Size Forecast
1.2.1 Global Influenza A Vaccine Sales Value (2019-2030)
1.2.2 Global Influenza A Vaccine Sales Volume (2019-2030)
1.2.3 Global Influenza A Vaccine Sales Price (2019-2030)
1.3 Influenza A Vaccine 麻豆原创 Trends & Drivers
1.3.1 Influenza A Vaccine Industry Trends
1.3.2 Influenza A Vaccine 麻豆原创 Drivers & Opportunity
1.3.3 Influenza A Vaccine 麻豆原创 Challenges
1.3.4 Influenza A Vaccine 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Influenza A Vaccine Players Revenue Ranking (2023)
2.2 Global Influenza A Vaccine Revenue by Company (2019-2024)
2.3 Global Influenza A Vaccine Players Sales Volume Ranking (2023)
2.4 Global Influenza A Vaccine Sales Volume by Company Players (2019-2024)
2.5 Global Influenza A Vaccine Average Price by Company (2019-2024)
2.6 Key Manufacturers Influenza A Vaccine Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Influenza A Vaccine Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Influenza A Vaccine
2.9 Influenza A Vaccine 麻豆原创 Competitive Analysis
2.9.1 Influenza A Vaccine 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Influenza A Vaccine Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza A Vaccine as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Intramuscular Vaccine
3.1.2 Nasal Spray Vaccine
3.2 Global Influenza A Vaccine Sales Value by Type
3.2.1 Global Influenza A Vaccine Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Influenza A Vaccine Sales Value, by Type (2019-2030)
3.2.3 Global Influenza A Vaccine Sales Value, by Type (%) (2019-2030)
3.3 Global Influenza A Vaccine Sales Volume by Type
3.3.1 Global Influenza A Vaccine Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Influenza A Vaccine Sales Volume, by Type (2019-2030)
3.3.3 Global Influenza A Vaccine Sales Volume, by Type (%) (2019-2030)
3.4 Global Influenza A Vaccine Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 3-18 Years Old
4.1.2 Above 18 Years Old
4.2 Global Influenza A Vaccine Sales Value by Application
4.2.1 Global Influenza A Vaccine Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Influenza A Vaccine Sales Value, by Application (2019-2030)
4.2.3 Global Influenza A Vaccine Sales Value, by Application (%) (2019-2030)
4.3 Global Influenza A Vaccine Sales Volume by Application
4.3.1 Global Influenza A Vaccine Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Influenza A Vaccine Sales Volume, by Application (2019-2030)
4.3.3 Global Influenza A Vaccine Sales Volume, by Application (%) (2019-2030)
4.4 Global Influenza A Vaccine Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Influenza A Vaccine Sales Value by Region
5.1.1 Global Influenza A Vaccine Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Influenza A Vaccine Sales Value by Region (2019-2024)
5.1.3 Global Influenza A Vaccine Sales Value by Region (2025-2030)
5.1.4 Global Influenza A Vaccine Sales Value by Region (%), (2019-2030)
5.2 Global Influenza A Vaccine Sales Volume by Region
5.2.1 Global Influenza A Vaccine Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Influenza A Vaccine Sales Volume by Region (2019-2024)
5.2.3 Global Influenza A Vaccine Sales Volume by Region (2025-2030)
5.2.4 Global Influenza A Vaccine Sales Volume by Region (%), (2019-2030)
5.3 Global Influenza A Vaccine Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Influenza A Vaccine Sales Value, 2019-2030
5.4.2 North America Influenza A Vaccine Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Influenza A Vaccine Sales Value, 2019-2030
5.5.2 Europe Influenza A Vaccine Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Influenza A Vaccine Sales Value, 2019-2030
5.6.2 Asia Pacific Influenza A Vaccine Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Influenza A Vaccine Sales Value, 2019-2030
5.7.2 South America Influenza A Vaccine Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Influenza A Vaccine Sales Value, 2019-2030
5.8.2 Middle East & Africa Influenza A Vaccine Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Influenza A Vaccine Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Influenza A Vaccine Sales Value
6.2.1 Key Countries/Regions Influenza A Vaccine Sales Value, 2019-2030
6.2.2 Key Countries/Regions Influenza A Vaccine Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Influenza A Vaccine Sales Value, 2019-2030
6.3.2 United States Influenza A Vaccine Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Influenza A Vaccine Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Influenza A Vaccine Sales Value, 2019-2030
6.4.2 Europe Influenza A Vaccine Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Influenza A Vaccine Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Influenza A Vaccine Sales Value, 2019-2030
6.5.2 China Influenza A Vaccine Sales Value by Type (%), 2023 VS 2030
6.5.3 China Influenza A Vaccine Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Influenza A Vaccine Sales Value, 2019-2030
6.6.2 Japan Influenza A Vaccine Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Influenza A Vaccine Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Influenza A Vaccine Sales Value, 2019-2030
6.7.2 South Korea Influenza A Vaccine Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Influenza A Vaccine Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Influenza A Vaccine Sales Value, 2019-2030
6.8.2 Southeast Asia Influenza A Vaccine Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Influenza A Vaccine Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Influenza A Vaccine Sales Value, 2019-2030
6.9.2 India Influenza A Vaccine Sales Value by Type (%), 2023 VS 2030
6.9.3 India Influenza A Vaccine Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Novartis
7.1.1 Novartis Company Information
7.1.2 Novartis Introduction and Business Overview
7.1.3 Novartis Influenza A Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Novartis Influenza A Vaccine Product Offerings
7.1.5 Novartis Recent Development
7.2 Sanofi
7.2.1 Sanofi Company Information
7.2.2 Sanofi Introduction and Business Overview
7.2.3 Sanofi Influenza A Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Sanofi Influenza A Vaccine Product Offerings
7.2.5 Sanofi Recent Development
7.3 GSK
7.3.1 GSK Company Information
7.3.2 GSK Introduction and Business Overview
7.3.3 GSK Influenza A Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.3.4 GSK Influenza A Vaccine Product Offerings
7.3.5 GSK Recent Development
7.4 Medimmune
7.4.1 Medimmune Company Information
7.4.2 Medimmune Introduction and Business Overview
7.4.3 Medimmune Influenza A Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Medimmune Influenza A Vaccine Product Offerings
7.4.5 Medimmune Recent Development
7.5 Abbott
7.5.1 Abbott Company Information
7.5.2 Abbott Introduction and Business Overview
7.5.3 Abbott Influenza A Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Abbott Influenza A Vaccine Product Offerings
7.5.5 Abbott Recent Development
7.6 Mitsubishi Tanabe Pharma
7.6.1 Mitsubishi Tanabe Pharma Company Information
7.6.2 Mitsubishi Tanabe Pharma Introduction and Business Overview
7.6.3 Mitsubishi Tanabe Pharma Influenza A Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Mitsubishi Tanabe Pharma Influenza A Vaccine Product Offerings
7.6.5 Mitsubishi Tanabe Pharma Recent Development
7.7 Merck
7.7.1 Merck Company Information
7.7.2 Merck Introduction and Business Overview
7.7.3 Merck Influenza A Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Merck Influenza A Vaccine Product Offerings
7.7.5 Merck Recent Development
7.8 Sinovac Biotech
7.8.1 Sinovac Biotech Company Information
7.8.2 Sinovac Biotech Introduction and Business Overview
7.8.3 Sinovac Biotech Influenza A Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Sinovac Biotech Influenza A Vaccine Product Offerings
7.8.5 Sinovac Biotech Recent Development
7.9 Hualan Biological Engineering
7.9.1 Hualan Biological Engineering Company Information
7.9.2 Hualan Biological Engineering Introduction and Business Overview
7.9.3 Hualan Biological Engineering Influenza A Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Hualan Biological Engineering Influenza A Vaccine Product Offerings
7.9.5 Hualan Biological Engineering Recent Development
7.10 Changsheng Bio-Technology
7.10.1 Changsheng Bio-Technology Company Information
7.10.2 Changsheng Bio-Technology Introduction and Business Overview
7.10.3 Changsheng Bio-Technology Influenza A Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Changsheng Bio-Technology Influenza A Vaccine Product Offerings
7.10.5 Changsheng Bio-Technology Recent Development
7.11 Beijing Tiantan Bio-Products
7.11.1 Beijing Tiantan Bio-Products Company Information
7.11.2 Beijing Tiantan Bio-Products Introduction and Business Overview
7.11.3 Beijing Tiantan Bio-Products Influenza A Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Beijing Tiantan Bio-Products Influenza A Vaccine Product Offerings
7.11.5 Beijing Tiantan Bio-Products Recent Development
8 Industry Chain Analysis
8.1 Influenza A Vaccine Industrial Chain
8.2 Influenza A Vaccine Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Influenza A Vaccine Sales Model
8.5.2 Sales Channel
8.5.3 Influenza A Vaccine Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Novartis
Sanofi
GSK
Medimmune
Abbott
Mitsubishi Tanabe Pharma
Merck
Sinovac Biotech
Hualan Biological Engineering
Changsheng Bio-Technology
Beijing Tiantan Bio-Products

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.